| Values |
---|---|
Classification, n (%) | |
 MPA | 32 (53.3) |
 GPA | 17 (28.3) |
 EGPA | 11 (18.3) |
Demographic data | |
 Age, years | 59.4 (14.3) |
 Female gender, n (%) | 40 (66.7) |
 New onset AAV, n (%) | 23 (38.3) |
 Disease duration, months†| 2.4 (23.9) |
AAV-related parameter | |
 BVAS†| 7.0 (10.5) |
 FFS (2009) †| 1.0 (1.0) |
 VDI†| 3.0 (2.0) |
 SF-36 PCS score | 50.5 (22.4) |
 SF-36 MCS score | 58.3 (20.1) |
Clinical features (organ involvement), n (%) | |
 General manifestation | 17 (28.3) |
 Cutaneous manifestation | 7 (11.7) |
 Mucous membrane and eye manifestation | 3 (5.0) |
 Ear, nose, and throat manifestation | 25 (41.7) |
 Pulmonary manifestation | 37 (61.7) |
 Cardiovascular manifestation | 3 (5.0) |
 Abdominal manifestation | 1 (1.7) |
 Renal manifestation | 33 (55.0) |
 Nervous system manifestation | 12 (20.0) |
ANCA positivity, n (%) | |
 ANCA double positivity | 1 (1.7) |
 MPO-ANCA (or P-ANCA) positivity | 37 (61.7) |
 PR3-ANCA (or C-ANCA) positivity | 7 (11.7) |
 ANCA negativity | 17 (28.3) |
Laboratory data | |
 White blood cell count, /mm3†| 7345.0 (5380.0) |
 Neutrophil count, /mm3†| 5000.0 (4790.0) |
 Platelet count, × 1000/mm3†| 254.0 (139.0) |
 ESR, mm/h†| 30.0 (31.5) |
 CRP, mg/L†| 1.4 (8.1) |
 Creatinine, mg/dL†| 1.0 (1.4) |
 AST, IU/L†| 18.0 (7.0) |
 ALT, IU/L†| 18.5 (13.5) |
 Serum YKL-40, ng/mL†| 189.2 (190.7) |
Concurrent immunosuppressive agents, n (%) | |
 Glucocorticoid | 42 (70.0) |
 Cyclophosphamide | 8 (13.3) |
 Rituximab | 1 (1.7) |
 Azathioprine | 14 (23.3) |
 Tacrolimus | 3 (5.0) |
 Mycophenolate mofetil | 2 (3.3) |
 Methotrexate | 2 (3.3) |